SCHEMBL27420904

SCHEMBL27420904

Cc1ccc(CNC(=O)N(C)[C@@H]2CCCN(c3cccnn3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 7/20 0.45
GLS O94925 2/20 0.44
KDM4E B2RXH2 1/20 0.43
RAB9A P51151 1/20 0.43
GPBAR1 Q8TDU6 1/20 0.43
MAPT P10636 1/20 0.42
CCR5 P51681 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
CYP2C19 P33261 1/20 0.42
HPGD P15428 1/20 0.41
EPHX2 P34913 1/20 0.41
IGF1R P08069 2/20 0.41
TP53 P04637 2/20 0.40
NPC1 O15118 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27417456 1.00 ALK (0.45) ALKGLSKDM4ERAB9AGPBAR1
SCHEMBL27417603 0.92 GLS (0.44) GLSKDM4EMAPTCCR5
SCHEMBL31754187 0.92 GPBAR1 (0.44) ALKGLSGPBAR1MAPTCCR5
SCHEMBL27422024 0.92 GPBAR1 (0.44) ALKGLSGPBAR1MAPTCCR5
SCHEMBL31754172 0.92 GLS (0.44) GLSKDM4EMAPTCCR5
SCHEMBL27420100 0.92 GLS (0.42) ALKGLSKDM4EGPBAR1CCR5
SCHEMBL27417608 0.92 GPBAR1 (0.44) ALKGLSGPBAR1MAPTCCR5
SCHEMBL31754167 0.91 GLS (0.43) ALKGLSKDM4ERAB9ACCR5
SCHEMBL27418028 0.91 GLS (0.45) ALKGLSKDM4ERAB9AMAPT
SCHEMBL27422542 0.91 GLS (0.43) ALKGLSKDM4ERAB9ACCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001859-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2026-01-01 US disclosed
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2024-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC18A2, SLC6A19, SLC1A1 ALK 4616/4885GLS 55/4885KDM4E 4275/4885
US-20260001859-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC6A19, SLC6A15, SLC6A2 ALK 1218/4885GLS 224/4885KDM4E 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.